Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma
A potential new first-line immunotherapy treatment for mesothelioma is now recruiting patients for a phase 3 clinical trial. The trial…
-
-
Immunotherapy with Keytruda for Mesothelioma: A New Case Report
There’s more encouraging news about immunotherapy with Keytruda for people with pleural mesothelioma. The latest report comes from the… -
New Cancer Vaccine Might Help Resistant Mesothelioma
Researchers at Harvard are developing a new cancer vaccine. Preliminary data suggest that it might work just as well as… -
CAR T-Cell Therapy for Mesothelioma in New Phase I Trial
Researchers at Memorial Sloan Kettering in New York are about to try a new kind of CAR T-cell therapy for… -
T-Cells Test May Predict Success of New Drug Combination for Mesothelioma
A month after the FDA approved a new drug combination for pleural mesothelioma, scientists are discovering more about who might… -
Study to Test Nivolumab and Chemotherapy for Mesothelioma
Researchers in Germany are recruiting patients for a trial of nivolumab and chemotherapy for pleural mesothelioma patients who have had… -
Europe | Immunotherapy | International | New Drugs | Treatments | Updates
First Patient Dosed in New Trial for Relapsed Mesothelioma
Doctors in the UK have started treatment on the first patient in the trial of a new drug combination for… -
“Exceptional Survival” in Some Patients on Nivolumab for Mesothelioma
A real-world study of Dutch patients suggests that nivolumab for mesothelioma can dramatically extend survival in the right patients. Nivolumab… -
Novel Strategy May Improve Immuno-radiotherapy for Mesothelioma
Canadian scientists say suppressing certain kinds of immune system cells could improve the effectiveness of immuno-radiotherapy for mesothelioma. Mesothelioma is… -
Manipulating “Fight or Flight” Could Impact Effectiveness of Immunotherapy for Mesothelioma
Doctors at the University of Connecticut may have found a way to influence the effectiveness of immunotherapy by manipulating the…
